Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data
Charles E. Geyer(Magee-Womens Hospital), David Cameron(Corewell Health), Cristina Oliva(Universidad de Huelva), Anne Marie Martin(GlaxoSmithKline (United Kingdom)), Michelle Casey(GlaxoSmithKline (United Kingdom)), B. Newstat(GlaxoSmithKline (United Kingdom)), S. Stein(GlaxoSmithKline (United Kingdom)), S. D. Rubin(GlaxoSmithKline (United States)), M. S. Berger(Duke University)
Cited by 32
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
|New England Journal of Medicine|2021|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k